Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Testing for HCV markers

H W Reesink1, C L van der Poel, D Bresters

  • 1Red Cross Blood Bank Amsterdam, The Netherlands.

Developments in Biological Standardization
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cyclophosphamide is not associated with clinically relevant late pulmonary dysfunction in Dutch survivors of childhood cancer - The DCCSS-LATER 2 PULM sub-study.

Respiratory medicine·2025
Same author

[A PhD completed. Long-term effects of childhood cancer therapy on oral health].

Nederlands tijdschrift voor tandheelkunde·2024
Same author

Chronic fatigue in childhood cancer survivors is associated with lifestyle and psychosocial factors; a DCCSS LATER study.

ESMO open·2023
Same author

Health-related quality of life in Dutch adult survivors of childhood cancer: A nation-wide cohort study.

European journal of cancer (Oxford, England : 1990)·2021
Same author

Pregnancy, time to pregnancy and obstetric outcomes among female childhood cancer survivors: results of the DCOG LATER-VEVO study.

Journal of cancer research and clinical oncology·2020
Same author

Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve.

Human reproduction (Oxford, England)·2018
Same journal

International challenges and public policy issues.

Developments in biological standardization·2000
Same journal

Regulation of biologicals in China.

Developments in biological standardization·2000
Same journal

ICH activities on biotech topics.

Developments in biological standardization·2000
Same journal

Regulation of biologicals in the European Union.

Developments in biological standardization·2000
Same journal

Standardisation and licensing of combination vaccines based on DTP.

Developments in biological standardization·2000
Same journal

Control of foot-and-mouth disease by vaccination.

Developments in biological standardization·2000
See all related articles

Researchers identified the hepatitis C virus (HCV) agent and developed sensitive antibody tests. Detection of HCV-RNA via PCR confirms infection and monitors treatment response in chronic hepatitis C patients.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • The agent of non-A/non-B (NANB) hepatitis remained unidentified until 1988.
  • Early diagnostic methods for NANB hepatitis lacked specificity and sensitivity.

Purpose of the Study:

  • To identify the causative agent of NANB hepatitis.
  • To develop sensitive diagnostic assays for hepatitis C virus (HCV).
  • To establish methods for monitoring HCV infection and treatment response.

Main Methods:

  • Blind expression cloning to identify viral polypeptides.
  • Development of radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA) using recombinant HCV antigens.
  • Application of recombinant immunoblot assays (RIBA) and dot immunoblot assays for confirmation.

Related Experiment Videos

  • Use of complementary DNA-polymerase chain reaction (cDNA-PCR) targeting the HCV 5' untranslated region (5'UTR) for RNA detection.

    • Main Results:

    • Identification of HCV-specific polypeptides (e.g., C-100, C-200, C33c, C22) through expression cloning.
    • Development of increasingly sensitive second-generation anti-HCV antibody tests.
    • Successful detection of HCV-RNA in serum and liver tissue using cDNA-PCR.
    • Demonstration of HCV-RNA disappearance via PCR as an indicator of successful antiviral therapy.

    Conclusions:

    • The agent of NANB hepatitis was identified as HCV, leading to diagnostic advancements.
    • Sensitive antibody and RNA detection methods are crucial for diagnosing and managing HCV infection.
    • cDNA-PCR is a valuable tool for confirming HCV viremia and assessing therapeutic efficacy in chronic hepatitis C.